iBet uBet web content aggregator. Adding the entire web to your favor.

This statistic displays the share of orphan medicines approved by the European Medicines Agency (EMA) between 2019 and 2022 which were available to patients in selected European countries as of January 5, 2024. According to the data, 89 percent of approved orphan medicines were available to patients in Germany, followed by 71 percent in Italy.

Percentage of orphan drugs approved by the EMA available to patients in Europe as of 2024, by country

Characteristic	Share of medicines available
Germany	89%
Italy	71%
France	68%
Austria	67%
Czech Republic	57%
Switzerland	54%
Spain**	51%
Portugal	51%
Denmark	51%
England	44%
Bulgaria	43%
Greece	41%
Scotland	40%
Luxemburg	40%
Netherlands	38%
Slovenia	37%
Belgium	35%
Poland	32%
Sweden	24%
Iceland	24%
Finland	24%
Cyprus*	22%
Romania	19%
Norway	19%
Hungary	19%
Ireland	14%
Croatia*	14%
Latvia	11%
Estonia	11%
Slovakia	6%
Serbia	6%
North Macedonia*	6%
Malta*	5%
Bosnia and Herzegovina*	5%
Turkey	2%
Lithuania	2%

Loading statistic...

Download

Source

Show detailed source information?

Already a member?

Sources

Use Ask Statista Research Service

Release date

June 2024

More information

Region

Europe

Survey time period

as of January 5, 2024

Supplementary notes

63 orphan drug products were approved by the European Medicines Agency between 2019 and 2022.
In most countries, availability equates to granting of access to the reimbursement list, except in DK, FI, LU, NO, SE some hospital products are not covered by the general reimbursement scheme.
* Country did not complete a full dataset and therefore availability may be unrepresentative.
** In Spain, the WAIT analysis does not identify those medicinal products being accessible earlier in conformity with Spain's Royal Decree 1015/2009 relating to Medicines in Special Situations.

Citation formats